CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.

NCT Number	NCT04495153
Lead Sponsor	Candel Therapeutics, Inc. Collaborators: NYU Langone Health
Conditions	Non Small Cell Lung Cancer
Enrollment	90 participants
Start Date	2020-10-13
Primary Completion	2024-12-31 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-22